Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:hypoxanthine
go back to main search page
Accession:CHEBI:17368 term browser browse the term
Definition:A purine nucleobase that consists of purine bearing an oxo substituent at position 6.
Synonyms:exact_synonym: 1,7-dihydro-6H-purin-6-one
 related_synonym: 6(1H)-purinone;   6-oxopurine;   9H-purin-6(1H)-one;   Formula=C5H4N4O;   Hyp;   InChI=1S/C5H4N4O/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10);   InChIKey=FDGQSTZJBFJUBT-UHFFFAOYSA-N;   Purine-6-ol;   SMILES=O=c1[nH]cnc2nc[nH]c12;   purin-6(1H)-one
 alt_id: CHEBI:14431;   CHEBI:24762;   CHEBI:43237;   CHEBI:5841
 xref: Beilstein:5811;   CAS:68-94-0;   DrugBank:DB04076;   ECMDB:ECMDB00157;   Gmelin:464558;   HMDB:HMDB0000157;   KEGG:C00262;   KNApSAcK:C00001502
 xref_mesh: MESH:D019271
 xref: MetaCyc:HYPOXANTHINE;   PDBeChem:HPA;   PMID:14253484;   PMID:1557408;   PMID:22735334;   PMID:23400363;   PMID:23670363;   PMID:8016081;   Reaxys:5811;   Wikipedia:Hypoxanthine;   YMDB:YMDB00555



show annotations for term's descendants           Sort by:
 
hypoxanthine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcg2 ATP binding cassette subfamily G member 2 multiple interactions ISO [Oxonic Acid analog co-treated with Hypoxanthine] results in decreased expression of ABCG2 mRNA; [Oxonic Acid analog co-treated with Hypoxanthine] results in decreased expression of ABCG2 protein; Allopurinol inhibits the reaction [[Oxonic Acid analog co-treated with Hypoxanthine] results in decreased expression of ABCG2 mRNA]; Allopurinol inhibits the reaction [[Oxonic Acid analog co-treated with Hypoxanthine] results in decreased expression of ABCG2 protein]; Polysaccharides inhibits the reaction [[Oxonic Acid analog co-treated with Hypoxanthine] results in decreased expression of ABCG2 mRNA]; Polysaccharides inhibits the reaction [[Oxonic Acid analog co-treated with Hypoxanthine] results in decreased expression of ABCG2 protein] CTD PMID:34687833 NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
JBrowse link
G Alpi alkaline phosphatase, intestinal multiple interactions ISO Hypoxanthine inhibits the reaction [Methotrexate results in increased activity of ALPI protein] CTD PMID:16598758 NCBI chr 9:87,773,411...87,776,877
Ensembl chr 9:87,773,411...87,776,877
JBrowse link
G B3gat3 beta-1,3-glucuronyltransferase 3 multiple interactions EXP [XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucosamine results in increased expression of B3GAT3 mRNA]; [XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucose results in increased expression of B3GAT3 mRNA] CTD PMID:11801247 NCBI chr 1:205,817,374...205,823,928
Ensembl chr 1:205,817,378...205,837,807
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO [Mycophenolic Acid co-treated with Hypoxanthine] results in increased expression of BAX protein CTD PMID:21396949 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO [3-hydrogenkwadaphnin co-treated with Hypoxanthine] results in decreased expression of BCL2 protein; [3-hydrogenkwadaphnin co-treated with Hypoxanthine] results in increased expression of BCL2 protein; [Mycophenolic Acid co-treated with Hypoxanthine] results in decreased expression of BCL2 protein CTD PMID:21396949 NCBI chr13:22,689,783...22,853,920 JBrowse link
G Casp3 caspase 3 multiple interactions ISO [3-hydrogenkwadaphnin co-treated with Hypoxanthine] results in increased activity of CASP3 protein; [Mycophenolic Acid co-treated with Hypoxanthine] results in increased activity of CASP3 protein CTD PMID:21396949 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO [Hypoxanthine co-treated with potassium oxonate] inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IL1B mRNA] CTD PMID:33749747 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il6 interleukin 6 multiple interactions ISO [Hypoxanthine co-treated with potassium oxonate] inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IL6 mRNA] CTD PMID:33749747 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Mtr 5-methyltetrahydrofolate-homocysteine methyltransferase multiple interactions ISO [Thymidine co-treated with Hypoxanthine co-treated with 5,6,7,8-tetrahydrofolic acid] inhibits the reaction [Methotrexate results in decreased expression of MTR protein]; [Thymidine co-treated with Hypoxanthine] inhibits the reaction [Methotrexate results in decreased expression of MTR protein] CTD PMID:16598758 NCBI chr17:58,219,998...58,308,560
Ensembl chr17:58,220,071...58,304,822
JBrowse link
G Nfatc1 nuclear factor of activated T-cells 1 decreases activity ISO Hypoxanthine results in decreased activity of NFATC1 protein CTD PMID:12203019 NCBI chr18:74,046,421...74,156,041
Ensembl chr18:74,046,904...74,156,028
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions ISO [Hypoxanthine co-treated with potassium oxonate] inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of NOS2 mRNA] CTD PMID:33749747 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO [Hypoxanthine co-treated with potassium oxonate] inhibits the reaction [1-Naphthylisothiocyanate results in increased phosphorylation of RELA protein] CTD PMID:33749747 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
JBrowse link
G Slc17a1 solute carrier family 17 member 1 multiple interactions ISO [Oxonic Acid analog co-treated with Hypoxanthine] results in decreased expression of SLC17A1 mRNA; [Oxonic Acid analog co-treated with Hypoxanthine] results in decreased expression of SLC17A1 protein; Allopurinol inhibits the reaction [[Oxonic Acid analog co-treated with Hypoxanthine] results in decreased expression of SLC17A1 mRNA]; Allopurinol inhibits the reaction [[Oxonic Acid analog co-treated with Hypoxanthine] results in decreased expression of SLC17A1 protein]; Polysaccharides inhibits the reaction [[Oxonic Acid analog co-treated with Hypoxanthine] results in decreased expression of SLC17A1 protein] CTD PMID:34687833 NCBI chr17:41,219,461...41,255,199
Ensembl chr17:41,222,049...41,253,304
JBrowse link
G Slc22a12 solute carrier family 22 member 12 multiple interactions ISO [Oxonic Acid analog co-treated with Hypoxanthine] results in increased expression of SLC22A12 mRNA; [Oxonic Acid analog co-treated with Hypoxanthine] results in increased expression of SLC22A12 protein; Allopurinol inhibits the reaction [[Oxonic Acid analog co-treated with Hypoxanthine] results in increased expression of SLC22A12 mRNA]; Allopurinol inhibits the reaction [[Oxonic Acid analog co-treated with Hypoxanthine] results in increased expression of SLC22A12 protein]; Polysaccharides inhibits the reaction [[Oxonic Acid analog co-treated with Hypoxanthine] results in increased expression of SLC22A12 mRNA]; Polysaccharides inhibits the reaction [[Oxonic Acid analog co-treated with Hypoxanthine] results in increased expression of SLC22A12 protein] CTD PMID:34687833 NCBI chr 1:203,845,039...203,852,496
Ensembl chr 1:203,845,048...203,853,555
JBrowse link
G Slc22a6 solute carrier family 22 member 6 multiple interactions ISO [Oxonic Acid analog co-treated with Hypoxanthine] results in decreased expression of SLC22A6 mRNA; [Oxonic Acid analog co-treated with Hypoxanthine] results in decreased expression of SLC22A6 protein; Allopurinol inhibits the reaction [[Oxonic Acid analog co-treated with Hypoxanthine] results in decreased expression of SLC22A6 mRNA]; Allopurinol inhibits the reaction [[Oxonic Acid analog co-treated with Hypoxanthine] results in decreased expression of SLC22A6 protein]; Polysaccharides inhibits the reaction [[Oxonic Acid analog co-treated with Hypoxanthine] results in decreased expression of SLC22A6 mRNA]; Polysaccharides inhibits the reaction [[Oxonic Acid analog co-treated with Hypoxanthine] results in decreased expression of SLC22A6 protein] CTD PMID:34687833 NCBI chr 1:205,522,579...205,531,179
Ensembl chr 1:205,522,729...205,531,173
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO [Hypoxanthine co-treated with potassium oxonate] inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of TNF mRNA] CTD PMID:33749747 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Xdh xanthine dehydrogenase multiple interactions
affects metabolic processing
ISO
EXP
[[Oxygen deficiency results in increased abundance of Hypoxanthine] affects the reaction [XDH protein affects the metabolism of Hypoxanthine]] which affects the abundance of Hydroxyl Radical; [XDH protein co-treated with Hypoxanthine] results in increased secretion of CXCL8 protein
[Oxonic Acid analog co-treated with Hypoxanthine] results in increased activity of XDH protein; Allopurinol inhibits the reaction [[Oxonic Acid analog co-treated with Hypoxanthine] results in increased activity of XDH protein]; Polysaccharides inhibits the reaction [[Oxonic Acid analog co-treated with Hypoxanthine] results in increased activity of XDH protein]
[XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucosamine results in increased abundance of Proteoglycans]; [XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucosamine results in increased expression of B3GAT3 mRNA]; [XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucose results in increased abundance of Proteoglycans]; [XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucose results in increased expression of B3GAT3 mRNA]
CTD PMID:7929072 PMID:8969274 PMID:11801247 PMID:34687833 NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
JBrowse link
inosine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ada adenosine deaminase decreases abundance
increases abundance
ISO ADA alternative form results in decreased abundance of Inosine
ADA protein results in increased abundance of Inosine
CTD PMID:16221767 NCBI chr 3:152,398,745...152,422,854
Ensembl chr 3:152,398,747...152,447,088
JBrowse link
G Faslg Fas ligand increases expression ISO Inosine results in increased expression of FASLG protein CTD PMID:16419169 NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
JBrowse link
G H2ax H2A.X variant histone multiple interactions ISO Inosine inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form] CTD PMID:32941855 NCBI chr 8:44,671,927...44,673,257
Ensembl chr 8:44,671,786...44,673,239
JBrowse link
G Slc29a1 solute carrier family 29 member 1 multiple interactions ISO
EXP
Inosine inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine] CTD PMID:9353301 PMID:11085929 NCBI chr 9:15,399,661...15,414,203
Ensembl chr 9:15,399,612...15,414,203
JBrowse link
G Slc29a2 solute carrier family 29 member 2 multiple interactions ISO Inosine inhibits the reaction [SLC29A2 protein results in increased uptake of Uridine] CTD PMID:11085929 NCBI chr 1:202,327,641...202,335,185
Ensembl chr 1:202,327,354...202,335,171
JBrowse link
G Tp53bp1 tumor protein p53 binding protein 1 multiple interactions ISO Inosine inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein] CTD PMID:32941855 NCBI chr 3:108,166,574...108,270,229
Ensembl chr 3:108,169,980...108,269,822
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 20056
    role 20008
      biological role 20007
        biochemical role 19640
          metabolite 19623
            fundamental metabolite 12801
              hypoxanthine 23
                9-riburonosylhypoxanthine 0
                inosine + 6
                methylhypoxanthine + 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 20056
    subatomic particle 20054
      composite particle 20054
        hadron 20054
          baryon 20054
            nucleon 20054
              atomic nucleus 20054
                atom 20054
                  main group element atom 19956
                    p-block element atom 19956
                      carbon group element atom 19882
                        carbon atom 19875
                          organic molecular entity 19875
                            organic molecule 19822
                              organic cyclic compound 19575
                                organic heterocyclic compound 18798
                                  organic heteropolycyclic compound 18272
                                    organic heterobicyclic compound 17159
                                      imidazopyrimidine 5633
                                        purines 5631
                                          aminopurine 4459
                                            6-aminopurines 831
                                              adenine 824
                                                hypoxanthine 23
                                                  9-riburonosylhypoxanthine 0
                                                  inosine + 6
                                                  methylhypoxanthine + 0
paths to the root